Alglucosidase Alfa (Lumizyme®)

Covered only for FDA‑approved Pompe disease (acid α‑glucosidase deficiency); uses outside that indication are not supported. Key requirements: diagnosis confirmed by enzyme assay or molecular genetic testing, prescribed by or in consultation with a geneticist, neurologist, metabolic disorder sub‑specialist or lysosomal storage disorder specialist, documented dosing of 20 mg/kg IV every 2 weeks, approvals limited to 12 months and subject to specified coverage/safety criteria and documentation.

"Lumizyme (alglucosidase alfa) is indicated for the treatment of individuals with Pompe disease (acid α-glucosidase deficiency)."

Sign up to see full coverage criteria, indications, and limitations.